These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37353972)

  • 1. The New Zealand drug harms ranking study: A multi-criteria decision analysis.
    Crossin R; Cleland L; Wilkins C; Rychert M; Adamson S; Potiki T; Pomerleau AC; MacDonald B; Faletanoai D; Hutton F; Noller G; Lambie I; Sheridan JL; George J; Mercier K; Maynard K; Leonard L; Walsh P; Ponton R; Bagshaw S; Muthukumaraswamy S; McIntosh T; Poot E; Gordon P; Sharry P; Nutt D; Boden J
    J Psychopharmacol; 2023 Sep; 37(9):891-903. PubMed ID: 37353972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Australian drug harms ranking study.
    Bonomo Y; Norman A; Biondo S; Bruno R; Daglish M; Dawe S; Egerton-Warburton D; Karro J; Kim C; Lenton S; Lubman DI; Pastor A; Rundle J; Ryan J; Gordon P; Sharry P; Nutt D; Castle D
    J Psychopharmacol; 2019 Jul; 33(7):759-768. PubMed ID: 31081439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing options for cannabis law reform: A Multi-Criteria Decision Analysis (MCDA) with stakeholders in New Zealand.
    Wilkins C; Rychert M; Queirolo R; Lenton SR; Kilmer B; Fischer B; Decorte T; Hansen P; Ombler F
    Int J Drug Policy; 2022 Jul; 105():103712. PubMed ID: 35537275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug harms in the UK: a multicriteria decision analysis.
    Nutt DJ; King LA; Phillips LD;
    Lancet; 2010 Nov; 376(9752):1558-65. PubMed ID: 21036393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranking the Harm of Psychoactive Drugs Including Prescription Analgesics to Users and Others-A Perspective of German Addiction Medicine Experts.
    Bonnet U; Specka M; Soyka M; Alberti T; Bender S; Grigoleit T; Hermle L; Hilger J; Hillemacher T; Kuhlmann T; Kuhn J; Luckhaus C; Lüdecke C; Reimer J; Schneider U; Schroeder W; Stuppe M; Wiesbeck GA; Wodarz N; McAnally H; Scherbaum N
    Front Psychiatry; 2020; 11():592199. PubMed ID: 33192740
    [No Abstract]   [Full Text] [Related]  

  • 6. A thematic analysis of MDMA-related harm and harm reduction experiences and knowledge in Aotearoa New Zealand.
    Whelan J; Ward RD; Noller G
    Harm Reduct J; 2024 May; 21(1):100. PubMed ID: 38783300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European rating of drug harms.
    van Amsterdam J; Nutt D; Phillips L; van den Brink W
    J Psychopharmacol; 2015 Jun; 29(6):655-60. PubMed ID: 25922421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prioritizing Healthcare Interventions: A Comparison of Multicriteria Decision Analysis and Cost-Effectiveness Analysis.
    Wilson R; Chua J; Pryymachenko Y; Pathak A; Sharma S; Abbott JH
    Value Health; 2022 Feb; 25(2):268-275. PubMed ID: 35094800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does perception of drug-related harm change with age? A cross-sectional online survey of young and older people.
    Cheeta S; Halil A; Kenny M; Sheehan E; Zamyadi R; Williams AL; Webb L
    BMJ Open; 2018 Nov; 8(11):e021109. PubMed ID: 30401725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring drug harm in New Zealand: a stocktake of current data sources.
    Crossin R; Cleland L; Rychert M; Wilkins C; Boden JM
    N Z Med J; 2022 May; 135(1554):93-104. PubMed ID: 35728221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranking the harm of non-medically used prescription opioids in the UK.
    van Amsterdam J; Phillips L; Henderson G; Bell J; Bowden-Jones O; Hammersley R; Ramsey J; Taylor P; Dale-Perera A; Melichar J; van den Brink W; Nutt D
    Regul Toxicol Pharmacol; 2015 Dec; 73(3):999-1004. PubMed ID: 26382614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA).
    Villanueva V; Carreño M; Gil-Nagel A; Serrano-Castro PJ; Serratosa JM; Toledo M; Álvarez-Barón E; Gil A; Subías-Labazuy S
    Epilepsy Behav; 2021 Sep; 122():108222. PubMed ID: 34371462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the harms of nicotine-containing products using the MCDA approach.
    Nutt DJ; Phillips LD; Balfour D; Curran HV; Dockrell M; Foulds J; Fagerstrom K; Letlape K; Milton A; Polosa R; Ramsey J; Sweanor D
    Eur Addict Res; 2014; 20(5):218-25. PubMed ID: 24714502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multi criteria decision analysis (MCDA) for evaluating and appraising government policy responses to non medical heroin use.
    Rolles S; Schlag AK; Measham F; Phillips L; Nutt D; Bergsvik D; Rogeberg O
    Int J Drug Policy; 2021 May; 91():103180. PubMed ID: 33640213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Weighing the benefits and harms of psychotropic and analgesic substances - A perspective of German addiction medicine experts].
    Bonnet U; Specka M; Soyka M; Alberti T; Bender S; Hilger J; Hillemacher T; Kuhlmann T; Kuhn J; Lüdecke C; Reimer J; Schneider U; Schroeder W; Stuppe M; Wiesbeck G; Wodarz N; Scherbaum N
    Fortschr Neurol Psychiatr; 2022 Jan; 90(1-02):19-29. PubMed ID: 33634461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries.
    Kurcevič E; Lines R
    Harm Reduct J; 2020 Nov; 17(1):94. PubMed ID: 33256747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.
    Hickie IB; Scott EM; Cross SP; Iorfino F; Davenport TA; Guastella AJ; Naismith SL; Carpenter JS; Rohleder C; Crouse JJ; Hermens DF; Koethe D; Markus Leweke F; Tickell AM; Sawrikar V; Scott J
    Med J Aust; 2019 Nov; 211 Suppl 9():S3-S46. PubMed ID: 31679171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia.
    Inotai A; Brixner D; Maniadakis N; Dwiprahasto I; Kristin E; Prabowo A; Yasmina A; Priohutomo S; Németh B; Wijaya K; Kalo Z
    BMC Health Serv Res; 2018 Dec; 18(1):1003. PubMed ID: 30594250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are government-approved products containing new psychoactive substances perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand.
    Rychert M; Wilkins C; Parker K; Witten K
    Drug Alcohol Rev; 2018 Mar; 37(3):406-413. PubMed ID: 29285812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population.
    van Amsterdam J; Opperhuizen A; Koeter M; van den Brink W
    Eur Addict Res; 2010; 16(4):202-7. PubMed ID: 20606445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.